Skip to main content

Accessible diagnostics are the key to combatting Antimicrobial Resistance

Modern science has made healthcare more elaborate than ever. For most people however, treatment for bacterial infections is based merely on symptoms, which increases the chance of misdiagnosis and prolonged disease course.

Proper diagnosis is limited to only a handful of people due to high costs, limited access to laboratories or healthcare facilities and a lack of experienced personnel.

Nostics is here to revolutionize diagnostics

There was no test that had it all…

 

…until now

Test anywhere

To help people in even the remote locations on earth.

Fast time-to-result

For correct treatment-decisions within a doctor’s visit.

User-friendly

To use without the need for highly experienced personnel.

Affordable (to all)

To make sure that when it’s available, it is really available.

So to really make a difference, we do not need another high-end, big and fancy machine.
We need point-of-care solutions that fit in your backpack.

Check out the Nostics solution

“If we don’t act now, by 2050 one person will die every three seconds due to Antimicrobial Resistance.”

“If we don’t act now, by 2050 one person will die every three seconds due to Antimicrobial Resistance.”

Only through steady action, we can ensure a bright future for our beautiful world.

What is Antimicrobial Resistance?

Antimicrobial resistance (or: AMR) is the unresponsiveness of bacteria to a certain antibiotic due to mutations or resistance genes the species has gained. This is a natural process, however, with the copious amounts of antibiotics that are used, this process is highly accelerated and becomes a danger to our healthcare system.

Antimicrobial-resistant infections currently claim at least 50,000 lives each year across Europa and the US alone.
By 2050, AMR will result in a 100.2 trillion USD loss in GDP.
In some countries more than 50% of patients with an E.coli infection don’t respond to first line antibiotics.
Between 2000 and 2010 antibiotics consumption rose nearly 40%.
People with MRSA infections are 64% more likely to die than people with drug-sensitive infections.
Gonorrhea has quickly developed resistance to all but one class of antibiotics.

Why are AMR rates rising?

Historical aspect

After their discovery, antibiotics were seen as the magic bullet and were therefore given more often than probably needed (if it doesn’t help, at least it doesn’t harm). But the more antibiotics are given (unnecessarily), the higher the chance of bacteria gaining resistance to it. Now we are for the first time seeing that this method might have its deficiencies, as more and more
bacteria species are becoming insensitive to standard treatment.

Healthcare Economics

Due to the low production costs of antibiotic drugs, it also seems much more cost-efficient to directly give antibiotics instead of first doing an (expensive) diagnostic test. When looking at the long term effects however, and considering the chances that incorrect antibiotics are given, the costs might in the end turn out much higher when somebody needs to be hospitalized for example.

Research Economics

Antibiotics research, or research into infectious diseases, is an under-funded research area because low return on investment (because it takes longer and longer to find new antibiotics and they are generally very cheap) and because it is often seen as ‘yesterday’s problem’ and the research focus has shifted towards non-communal diseases such as cancer. This resulted in less than 5% of venture capital investment between 2003 and 2013 was directed towards antimicrobial development.

Why are AMR rates rising?

Historical aspect

Antibiotics were treated as magic bullet that could be given "just in case". But the more antibiotics are given (unnecessarily), the higher the chance of bacteria gaining resistance to it. Now we are for the first time seeing that this method might have its deficiencies, as more and more bacteria species are becoming insensitive to standard treatment.

Healthcare Economics

Low production costs of antibiotic drugs make it seemingly more cost-efficient to directly give antibiotics instead of first doing an (expensive) diagnostic test. When looking at the long term effects however, the costs might in the end turn out much higher in case of misdiagnosis.

Research Economics

Research into infectious diseases, is an under-funded research area because low return on investment and because it is often seen as ‘yesterday’s problem’. This resulted in less than 5% of venture capital investment between 2003 and 2013 was directed towards antimicrobial development.

The Nostics solution: Point-of-Need bacterial identification

We are taking spectroscopy where it has never been before: bacterial identification. By combining spectroscopy with nanotechnology and advanced AI classification, we are soon launching a novel diagnostic tool for PoC bacterial infection identification.

This digital diagnostics platform can provide fast and accurate diagnostics for bacterial infections without the need for costly labs. By using a handheld device, Raman spectroscopy, cutting-edge nanosurfaces and advanced AI algorithms, we want to change the lives of people in places without access to bacterial diagnostics and accelerate this access in countries with more developed healthcare facilities.

The Nostics solution: Point-of-Need bacterial identification

We are taking spectroscopy where it has never been before: bacterial identification.

This digital diagnostics platform can provide fast and accurate diagnostics for bacterial infections without the need for costly labs. By using a handheld device, Raman spectroscopy, cutting-edge nanosurfaces and advanced AI, we want to change the lives of people in places without access to bacterial diagnostics and accelerate this access in countries with more developed healthcare facilities.

Available soon: Rapid Bacterial Colony ID

Colony picking

easy bacterial collection

Sample preparation

compatible with standard laboratory equipment

Measurement

in our handheld measuring device

Digital result

advanced AI classification within 30 seconds

Interested in our product?
Want to schedule a meeting for a demonstration or collaboration?
Or simply want to know more?

Let’s get in touch!

Close Menu

Nostics

HQ:
Fred Roeskestraat 115
1076 EE Amsterdam

Lab:
Alexander Fleminglaan 1
2613 AX Delft

T: +31(0)85 073 7100
E: info@nostics.com